Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: JAMA Intern Med. 2015 Jun;175(6):1062–1065. doi: 10.1001/jamainternmed.2015.0920

Table 2.

Prevalence of Antithrombotic Prescription in Atrial Fibrillation Patients at Low Stroke Risk with No Structural Heart Disease in Both the CHADS2 Score =0 and CHA2DS2-VASc Score =0 Cohorts

Therapy CHADS2 Score =0
Cohort
(N=10,995)		 CHA2DS2-VASc Score =0 Cohort
(N=6,730)
Antithrombotic therapy
 Any oral anticoagulant therapy only 16.0% 17.8 %
 Any oral anticoagulant therapy and any antiplatelet therapy 7.3% 8.8%
 Any antiplatelet therapy only 34.8% 38.1%
 No therapy 41.9% 35.3%

Categorical data are reported as percentages.

Oral anticoagulant therapy was defined as prescription of either warfarin, dabigatran, or rivaroxaban. Antiplatelet therapy was defined as prescription of either individual or combination of aspirin, clopidogrel, ticlopidine, prasugrel, and/or dipyridamole.